Friday, April 12, 2013
Memorial Sloan Kettering’s Virtual Programs offers patients private, online support and education sessions to participate in from home or work.
Monday, April 8, 2013
Memorial Sloan Kettering’s Physician-in-Chief, José Baselga, explains the findings from three studies on new targeted therapies for breast cancer.
Thursday, March 28, 2013
A study identifies genetic variations that alter the risk of breast cancer in women who have a certain gene mutation.
In the Lab
Wednesday, March 13, 2013
Scientists from Memorial Sloan Kettering have collaborated on the discovery of a unique monoclonal antibody, called ESK1, that appears to be effective at targeting and destroying several types of cancer cells.
In the Clinic
Monday, March 4, 2013
Peripheral neuropathy — a nerve disorder that can cause weakness, numbness, tingling, and pain — is a common chemotherapy side effect. Treatments are available to help improve your quality of life.
Friday, March 1, 2013
At the seventh annual seminar for high school students and teachers, investigators discuss how cutting-edge biomedical research may ultimately contribute to better treatments for cancer patients.
In the Lab
Thursday, January 3, 2013
A team from Memorial Sloan Kettering has found that the makeup of immune cells in a lung tumor and in tissue surrounding a tumor can predict whether the cancer will recur after surgery.
Thursday, December 27, 2012
Problems with cognitive function can significantly impact a person’s quality of life after cancer treatment. New research is focused on the link between cancer treatment and cognitive changes.
In the Lab
Tuesday, December 18, 2012
Memorial Sloan Kettering researchers have reported a new method that could allow the development of more-specific, cell-based therapies for cancer.
In the News
Friday, November 16, 2012
Memorial Sloan Kettering has been praised for taking a stand on the price for a new cancer drug that costs more than twice as much as another, similar drug.
Friday, November 2, 2012
Dr. Chi, a physician-scientist and member of the Human Oncology and Pathogenesis Program, studies genetic and epigenetic changes that cause cancer.
In the Lab
Monday, October 8, 2012
Researchers have produced a fully synthetic, functional version of erythropoietin, the hormone that controls production of red blood cells.
Monday, October 1, 2012
Dr. Barakat will serve as president of two prestigious societies for gynecologic cancer, allowing him to influence how women with these cancers are cared for both in the United States and around the world.
Wednesday, September 26, 2012
Dr. Rudensky studies the development of white blood cells called T lymphocytes, which participate in the immune system response to infection. He joined the Sloan Kettering Institute in 2009.
Friday, September 21, 2012
With the genomics revolution, scientists and physicians have increasingly been able to peer at the inner workings of tumor cells and pinpoint the specific genetic changes that transform them from their cells of origin into cancer.